Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab in Chemoresistant GTN
NCT05405192Phase 2Withdrawn
- Sponsor
- University of Miami
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab in gestational trophoblastic neoplasia (GTN), sponsored by University of Miami. Planned start Mar 2023; status: withdrawn.
02
Drugs
dostarlimab
03
Conditions
gestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT05405192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405192.